All Comments by Paul Coleman

  1. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.
  2. Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology.
  3. Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease.
  4. Principal component analysis of FDG PET in amnestic MCI.
  5. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
  6. Widespread changes in dendritic spines in a model of Alzheimer's disease.
  7. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
  8. Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium.
  9. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons.
  10. Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope.
  11. Telomere length in white blood cells, buccal cells and brain tissue and its variation with ageing and Alzheimer's disease.
  12. Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function.
  13. Biomarkers for early detection of Alzheimer pathology.
  14. In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes.
  15. Brain tissue microarrays in neurodegenerative diseases: validation of methodology and immunohistochemical study of growth-associated protein-43 and calretinin.